The dedicated biotech sessions at SLUSH enabled focused exchanges with key representatives from the life sciences and venture capital ecosystems. These formats offered a structured framework to discuss scientific approaches and gather feedback from various perspectives.

In addition, networking formats outside the core program, including German Beer Together and the Padel & Pitch side event, provided further opportunities for personal interaction. Padel & Pitch in particular proved to be a dynamic format that fostered professional exchange in a relaxed, sporty atmosphere and contributed to new connections in an enjoyable way.

myotwin draws a positive conclusion from its SLUSH experience and looks forward to a potential participation again next year.

Der Beitrag myotwin GmbH looks back on a successful debut at SLUSH 2025 in Helsinki. The international investor conference provided an ideal setting to present the company’s technology platform to a broad audience of investors and innovation stakeholders, while offering first insights into current developments. erschien zuerst auf myotwin.

For myotwin, BIO-Europe once again provided a valuable opportunity to showcase the latest advancements in human tissue models and digital cardiac simulations. Particularly encouraging was the strong interest in reliable, human-relevant data for cardiovascular drug development, a key topic in many conversations and a clear indication of the growing importance of this approach within the industry.

The exchange at the NRW joint booth was once again a highlight for myotwin. Numerous constructive and open discussions took place with committed companies from North Rhine-Westphalia. The strong local network and highly positive feedback underscored the relevance of new solutions emerging from the NRW region.

myotwin draws a very positive conclusion. The third participation in BIO-Europe further increased international visibility and generated valuable starting points for future partnerships. With many new insights from Vienna and the support of a strong regional ecosystem, the team now embarks on upcoming projects with fresh momentum.

Der Beitrag myotwin GmbH looks back on a successful participation at BIO-Europe 2025 in Vienna. For the third time, the company was represented at Europe’s most important partnering conference for the biotech and pharmaceutical industry. From November 3–5, experts from across Europe gathered to discuss current developments and emerging therapeutic approaches. erschien zuerst auf myotwin.

Overall, myotwin considers its first participation in ELRIG Drug Discovery a success. The event offered opportunities for scientific interaction, highlighted potential starting points for collaborations, and provided valuable impulses for the next steps.

Der Beitrag myotwin GmbH looks back on a successful first appearance at ELRIG Drug Discovery 2025 in Liverpool. The event offered the young company an excellent opportunity to present its work to a new scientific audience and to gather relevant insights for cardiovascular research. erschien zuerst auf myotwin.

Together with the BioCampus Cologne, RTZ forms part of Cologne’s high-tech hubs, home to more than 70 knowledge-based companies. These hubs offer start-ups, scale-ups, and corporates in the fields of deep tech, high tech, and STEM the ideal environment to transform ideas into successful business models. Tailored infrastructure – from offices and workshops to laboratories and event spaces – provides the framework for a lively, connected community.

myotwin extends its sincere thanks to the RTZ team for the warm welcome and looks forward to becoming part of this strong entrepreneurial community. With its new location, the company not only gains additional infrastructure but also an environment that actively fosters collaboration and innovation.

Der Beitrag As of August 1, myotwin GmbH has expanded its presence by moving into office space at the Rechtsrheinisches Technologie- und Gründerzentrum Cologne (RTZ). With this step, the biotech start-up continues to grow its business activities while strengthening its integration into Cologne’s high-tech ecosystem. erschien zuerst auf myotwin.

The participation was supported by the Federal Ministry for Economic Affairs and Energy (BMWE), BIO.NRW, and NRW.Global Business. In particular, the shared booth as part of the NRW pavilion proved to be of great value for myotwin’s presence at the convention. The company extends its sincere thanks for this support, which further strengthened its visibility on the international stage.

After numerous discussions, new contacts, and initial approaches to partnerships, myotwin draws a thoroughly positive conclusion from BIO 2025. The convention once again confirmed its importance as a platform to showcase innovation and to initiate the next phase of growth together with strong partners.

Der Beitrag For the second time, myotwin GmbH participated in the BIO International Convention, the world’s largest trade fair for biotechnology and pharmaceuticals. erschien zuerst auf myotwin.

A particular highlight was myotwin’s poster presentation “Heart Attack in a Dish.” The model, which replicates cardiovascular disease mechanisms at the cellular level, attracted strong interest from the international MPS community.

In addition, Dr.-Ing. Jan Pietras, co-founder of myotwin, contributed to the “Beat and Breath” session. He presented the company’s High-Content Screening Platform and joined discussions on the future of innovative disease models.

The conference was marked by lively discussions, inspiring presentations, and valuable exchange with the scientific community. myotwin extends its gratitude to EUROoCS and the International MPS Society for organizing such an outstanding event and looks forward to presenting further progress at next year’s conference.

Der Beitrag myotwin GmbH looks back on a successful participation at this year’s International MPS Society (iMPSS) conference in Brussels. erschien zuerst auf myotwin.

“We are very grateful for the support provided through the EXIST Research Transfer. It paved the way for us to bring our technology from research into practical application,” says Andreas Meyer-Borgstädt, co-founder and CEO of myotwin. “Our special thanks go to the Project Management Jülich, the University Medical Center Göttingen, and the University of Göttingen for their valuable support.”

With the successful completion of the EXIST Research Transfer, myotwin is well positioned to further pursue its mission: developing a digital twin of the human heart. This platform aims to make drug development for cardiovascular diseases faster, safer, and free of animal testing – ultimately benefiting millions of patients worldwide.

Der Beitrag The biotech start-up myotwin GmbH has successfully completed the EXIST Research Transferprogram. With funding from the Federal Ministry for Economic Affairs and Energy (BMWE), the foundation for the company spin-off was established and its technology platform significantly advanced. erschien zuerst auf myotwin.

The artificial production of heart muscle tissue offers a promising approach for the development of new drugs against cardiovascular diseases, which are the leading cause of death worldwide. The project “AI-based Optimization of the Production of Cardiac Bodies” aims to make the production process of Cardiac Bodies – a precursor of complete heart tissue – more efficient and robust. This will enable the production of functional heart tissue of high quality, which is essential for research as well as the development of innovative therapies.

AI and Biotechnology

Artificial intelligence will be applied in two specific areas of the project. On the one hand, the complex biotechnological production process itself will be optimized through machine learning. In addition, the research on Cardiac Bodies generates large volumes of data, which are managed using the LinkAhead data management system. To simplify data analysis, the search language of LinkAhead will be significantly enhanced by the use of Large Language Models (LLMs). This will particularly improve complex search queries.

The project is supported by NBank within the framework of the Lower Saxony Innovation Funding Program for Research and Development in Companies, co-financed by the European Union, and runs from May 1, 2025 to April 30, 2026.

Further information about the two Göttingen-based companies myotwin GmbH and IndiScale GmbH

Der Beitrag The biotech start-up myotwin GmbH and the data management company IndiScale GmbH are launching a joint project to optimize the production of artificially generated human mini-organs using artificial intelligence. erschien zuerst auf myotwin.

Participation in BIO-Europe Spring marks another step in myotwin’s international positioning. The company is already preparing for its next major milestones: the upcoming MPS World Summit in Brussels and the BIO International Convention in Boston this June, where myotwin will once again present its platform to a global audience and build on the partnerships initiated in Milan.

Der Beitrag Three days filled with discussions, meetings, and fresh inspiration: myotwin GmbH took part in BIO-Europe Spring 2025 in Milan and draws a thoroughly positive conclusion. The conference is one of the leading meeting points for the European biotech and pharma community and once again offered a dynamic environment for exchange and collaboration. erschien zuerst auf myotwin.

The myotwin team would like to thank all involved for their support, especially the State of Lower Saxony, NBank, the project sponsor, and the Life Science Valley in Göttingen for their close collaboration throughout the project.

With the successful completion of the HTI program, myotwin not only strengthens its own growth base but also contributes to the biotech hub Göttingen. The company is now ready to enter the next development phase and apply its technologies in further collaborations and studies.

Der Beitrag myotwin GmbH has successfully completed the HTI funding program of the State of Lower Saxony. The €200,000 funding project was coordinated through the Life Science Valley in Göttingen and enabled myotwin to successfully launch its business operations. erschien zuerst auf myotwin.